Trial Search Results

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

St. Jude Children's Research Hospital

Stanford Investigator(s):

Intervention(s):

  • Drug: Stanford V Chemotherapy
  • Radiation: Radiation Therapy

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Histologically confirmed, previously untreated Hodgkin lymphoma.

   - Age: Participants must be 21 years of age or younger

   - Stage must be classified as one of the following:

Ann Arbor stage IA or IIA with:

   - Non-bulky mediastinal disease (< 33% mediastinal to thoracic ratio on CXR)

   - < 3 nodal regions involved on the same side of the diaphragm

   - No "E" lesion

   - Female patients who are post-menarchal must have a negative pregnancy test. Patients
   of reproductive potential must agree to use an effective contraceptive method.

   - Signed informed consent

   - If re-evaluation of a patient's disease shows intermediate risk features, the patient
   will be removed from the HOD08.

Exclusion Criteria:

   - Intermediate or High risk disease, defined as Stage IB, any III or IV or IA/IIA with
   "E" lesion(s), 3 or more nodal sites involved, or bulky mediastinal adenopathy

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Regina Dagher
650-725-4041
Recruiting